Releases - Active Biotech

View:
 

Found press releases

 

Interim Report January - March 2001

14 May, 2001 17:59 CET
The Active Biotech Group


· Both key projects, SAIK-MS and TTS, are proceeding to Phase II
clinical trials

· Increased focus on research projects in Lund

· Financing through partnerships, possible sale of operations and
new share issue

· Operating loss of SEK -87.6 million for the period (SEK -51.5
million), adjusted pro...

Active Biotech fulfills important milestone for the SAIK-MS project

24 Apr, 2001 10:22 CET
The clinical Phase 1 study on Active Biotech's SAIK-MS compound, ABR-
215062 in healthy volunteers and MS patients is concluded.

The study has successfully reached its clinical endpoint, and has
provided the future clinical development programme with valuable
information.

A million people worldwide are affected by multiple sclerosis (MS), a
chronic autoimmune disease. The...

Annual General Meeting of Shareholders in Active Biotech 29 March 2001

30 Mar, 2001 11:01 CET
At Active Biotech AB´s Annual General Meeting Sven Andréasson, Mats
Arnhög, Maria Borelius, Svend Holst-Nielsen, Mats Pettersson, Peter
Sjöstrand and Hugo Thelin were re-elected. Hugo Thelin will continue
serving as Chairman of the Board.

Anders Williamsson and Håkan Åström, who have renounced a re-election
due to other commitments, were thanked for their services by the
Chairman...

Active Biotech in collaboration with Aventis Pasteur MSD regarding distribution ...

23 Mar, 2001 13:06 CET
Active Biotech in collaboration with Aventis Pasteur MSD regarding
distribution and marketing of vaccines in Sweden

Active Biotech AB, through its subsidiary SBL Vaccin AB, and Aventis
Pasteur MSD announce that they will initiate a collaboration regarding
marketing and distribution of vaccines, and will now start a close
collaboration on the Swedish market.

Invitation to Annual General Meeting of Shareholders

27 Feb, 2001 10:30 CET
The Board of Directors of Active Biotech AB (publ) has today issued a
notification of the Annual General Meeting, which is to take place at
17.00 on 29 March 2001 at the Scandic Star Hotel, Glimmervägen 5, in Lund.
The notification is published in today's editions of Sydsvenskan, Svenska
Dagbladet and Post- och Inrikes Tidningar.

ACTIVE BIOTECH AB (PUBL)

THE BOARD OF...

The Active Biotech Group Final Accounts Report For The 2000 Operating Year

19 Feb, 2001 14:47 CET
· SAIK-MS phase I study now also includes MS patients
· TTS phase I study completed
· GAS-vaccine - high protective effect
· Increase in vaccine sales by 26%
· Profit/loss after net financial items (before items affecting
comparability) MSEK -148.6 -according to forecast (MSEK -150)
· Profit/loss after items affecting comparability MSEK -419.3
million (MSEK -62.0)

Interim report

17 Nov, 2000 16:48 CET

Half-Year Accounts January - June 2000

18 Aug, 2000 18:28 CET
Half-Year Accounts
January - June 2000

* Results according to schedule, MSEK -59 (-75 previous year)
* Vaccine sales increase by 20%
* Continued positive development for Dukoral +42%
* Aventis Pasteur new business partner
* SAIK and TTS according to plan
* Major new order for SBL Cholera Vaccine worth MSEK 7.4
* New technology platforms established
* Increase in...

Active Biotech and SmithKline Beecham agree to close collaboration regarding vac...

8 Aug, 2000 10:41 CET
Active Biotech and SmithKline Beecham agree to close collaboration regarding
vaccines against traveller's diarrhoea

Active Biotech has taken back the worldwide rights for the ETEC vaccine
project. The ongoing phase III clinical trials in Mexico and Guatemala are
continuing according to plan. Alternative partnering strategies are under
evaluation as well as the future clinical trials...

Active Biotech concludes agreement with Aventis Pasteur

8 Aug, 2000 10:36 CET
Active Biotech has started collaboration with Aventis Pasteur within the
field of diarrhoea diseases.
Aventis Pasteur will assume responsibility for the marketing, sales and
distribution of Active Biotech's drinkable cholera vaccine, SBL Cholera
Vaccine for all countries worldwide outside USA and Europe. The product
has received a recommendation from the World Health Organisation (WHO),...

Active Biotech

RSS

Active Biotech's activity is in the biomedical area. The company focuses on R & D.

View more


  CONTACT